Please sign in to follow a disease.
Massive study reveals best arthritis drug combos for patients
NCT ID NCT05576051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at over 9,000 people with rheumatoid arthritis to compare how well different treatments work in everyday medical practice. Researchers compared drugs like TNF inhibitors and tofacitinib, given alone or with methotrexate, to see which combination controls disease activity best after 6 months. The goal was to help doctors choose the most effective treatment for each patient.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
9,159 people
The number who actually took part.
- Started
-
Jun 2015
- Finished
-
Oct 2015
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Observational retrospective data using the Corrona RA Registry
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * RA patients in Corrona initiating a TNFi biologic (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) during follow-up in Corrona with no prior use of Tofacitinib Exclusion Criteria: * Patients with no history of cDMARD but history of 1+ biologics - these cases will be excluded from analyses * Patients using combination therapy with a cDMARD other than MTX will be excluded * Patients using combination therapy of MTX and another cDMARD will be excluded
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new ankle? researchers track 400 people with an implant meant to restore movement
- Can a Job-Focused rehab program keep arthritis patients employed?
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Hidden kidney damage may lurk in rheumatoid arthritis patients
- Can a new injection calm rheumatoid arthritis? an early trial puts ZB002 to the test
- Can a new knee implant design offer better Long-Term relief?